Investor Relations

Alseres Pharmaceuticals, Inc (NASDAQ: ALSE) is a biotechnology company engaged in the development of biopharmaceutical products for the treatment of traumatic injuries and degenerative diseases. The Company maintains a world-class position in the field of regenerative therapeutics. Our energy and focus are reflected in several important initiatives. Our lead candidate, Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. Our molecular imaging program has a product candidate, ALTROPANE® molecular imaging agent, in Phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. The Company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. Our sponsored scientific research in ground-breaking regenerative technologies may someday make possible other therapies for stroke, spinal cord and ocular injuries, bone repair and cardiovascular indications.